Tarsus Pharmaceuticals, Inc.
TARS
Classement en actions
#4598
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Prix de l'action
$71.12
Dernière synchronisation: 2026-10-20
Capitalisation boursière
$3.33B
Changement (1 jour)
2.33%
Changement (1 an)
0.42%
Pays
US
Échange Tarsus Pharmaceuticals, Inc. (TARS)
Catégorie
Healthcare
Historique des divisions d’actions pour Tarsus Pharmaceuticals, Inc. (TARS)
L’action Tarsus Pharmaceuticals, Inc. (symbole : TARS) a subi un total de 0 divisions.
La division la plus récente a eu lieu le Oct 21, 2026.
Une action TARS achetée avant le Oct 21, 2026 équivaudrait aujourd’hui à 0 actions TARS.
La division la plus récente a eu lieu le Oct 21, 2026.
Une action TARS achetée avant le Oct 21, 2026 équivaudrait aujourd’hui à 0 actions TARS.
Liste des divisions d’actions
| Année | Division | Multiplicateur | Multiplicateur cumulatif |
|---|---|---|---|
| Pas assez de données pour les dates fournies. | |||
Divisions d’actions d’entreprises similaires ou concurrentes
| Entreprise | Nombre de divisions d’actions | Multiplicateur cumulatif | Pays |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|